Hertraz is a brand name for Trastuzumab 440 mg injection, which is used for the treatment of certain types of breast cancer that are positive for HER2 expression. Trastuzumab is a type of monoclonal antibody that targets the HER2 protein that is overexpressed on the surface of certain types of cancer cells, including breast cancer cells. Hertraz is manufactured by Mylan Laboratories Ltd. and is available in a vial containing 440 mg of trastuzumab.
Hertraz is typically used in combination with chemotherapy and/or hormonal therapy for the treatment of HER2-positive breast cancer. The medication is given as an injection into a vein and is administered by a healthcare professional in a hospital or clinic setting.
The recommended dose and duration of treatment with Hertraz will vary depending on the stage of breast cancer, the individual’s medical history, and other factors. Patients should follow the dosage and administration instructions carefully and receive regular medical check-ups to monitor their progress.
The safety and effectiveness of Hertraz have been studied in several clinical trials. These trials have shown that the medication can improve the response rate, disease-free survival, and overall survival in patients with HER2-positive breast cancer when given along with chemotherapy and/or hormonal therapy. However, Hertraz does come with potential side effects.
Common side effects of Hertraz may include fatigue, nausea, vomiting, diarrhea, fever, chills, and headache. More serious side effects can include heart problems, such as congestive heart failure or decrease in heart function, and infusion reactions, such as fever, chills, allergic reactions, and respiratory distress. Patients should report any side effects to their healthcare provider immediately.
Hertraz is not recommended for use in patients who have a history of allergic reactions to trastuzumab or other monoclonal antibody medications. It may also interact with other medications, so patients should inform their healthcare provider of all medications they are taking before starting treatment with Hertraz.
In summary, Hertraz is a medication used for the treatment of certain types of breast cancer that are positive for HER2 expression. It is a monoclonal antibody that targets the HER2 protein on breast cancer cells. Hertraz is given as an injection into a vein and is administered by a healthcare professional. While Hertraz has been shown to be effective in treating breast cancer, it does come with potential side effects that patients and healthcare providers should be aware of. Patients should also discuss any potential interactions with other medications with their healthcare provider before starting treatment with Hertraz.